U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. Drugs
  3. Development & Approval Process | Drugs
  4. Drug Approvals and Databases
  5. Resources for Information | Approved Drugs
  6. FDA approves carfilzomib and daratumumab with dexamethasone for multiple myeloma
  1. Resources for Information | Approved Drugs

FDA approves carfilzomib and daratumumab with dexamethasone for multiple myeloma

On August 20, 2020, the Food and Drug Administration approved  carfilzomib (KYPROLIS, Onyx Pharmaceuticals, Inc.) and daratumumab (DARZALEX, Janssen Biotech, Inc.) in combination with dexamethasone for adult patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy.

The efficacy of carfilzomib and daratumumab with dexamethasone was evaluated in two clinical trials, CANDOR and EQUULEUS.

CANDOR (NCT03158688) was a randomized, open label, multicenter trial evaluating the combination of carfilzomib (20/56 mg/m2 twice weekly regimen) with intravenous daratumumab and dexamethasone (DKd) versus carfilzomib (20/56 mg/m2 twice weekly regimen) and dexamethasone (Kd) in patients with relapsed or refractory multiple myeloma who had received 1 to 3 prior lines of therapy. A total of 466 patients were randomized; 312 to the DKd arm and 154 to the Kd arm.

Efficacy was assessed by an independent review committee (IRC) evaluation of progression-free survival (PFS) using International Myeloma Working Group (IMWG) response criteria. Median PFS was not reached for the DKd arm and was 15.8 months (95% CI: 12.1, NE) for the Kd arm (HR 0.63; 95% CI: 0.46, 0.85; 1-sided p-value 0.0014).

EQUULEUS (NCT01998971) was an open label, multicohort trial evaluating the combination of carfilzomib (20/70 mg/m2 once weekly regimen) with intravenous daratumumab and dexamethasone (DKd). Efficacy was based on overall response rate (ORR) as assessed by IRC  using IMWG response criteria.  Of the 85 patients with relapsed or refractory multiple myeloma who had received 1 to 3 prior lines of therapy enrolled in the DKd cohort, the ORR was 81% (95% CI: 71, 89) with a duration of response of 27.5 months (20.5, not estimable).

The most common adverse reactions occurring in at least 20% of patients treated with carfilzomib and daratumumab in the combination therapy trials were infusion related reactions, anemia, diarrhea, fatigue, hypertension, pyrexia, respiratory tract infection, thrombocytopenia, neutropenia, lymphopenia, cough, dyspnea, insomnia, headache and back pain.

The recommended dosage regimens of carfilzomib, when administered in combination with intravenous daratumumab and dexamethasone, are:

  • Once weekly 20/70 mg/m2 regimen:  administer carfilzomib intravenously as a 30-minute infusion on Days 1, 8, and 15 of each 28-day cycle at a dose of 20 mg/m2 on Cycle 1 Day 1 and, if tolerated, increased to 70 mg/m2 on Cycle 1 Day 8 and thereafter OR
  • Twice weekly 20/56 mg/m2 regimen:  administer carfilzomib intravenously as a 30-minute infusion on Days 1, 2, 8, 9, 15, and 16 of each 28-day cycle  at a dose of 20 mg/m2 on Days 1 and 2 of Cycle 1 and, if tolerated, increased to 56 mg/m2 on Cycle 1 Day 8 and thereafter.

The recommended dosage regimen of intravenous daratumumab, when administered in combination with carfilzomib and dexamethasone, is 16 mg/kg actual body weight administered as split dosing of 8 mg/kg on Days 1 and 2 of Cycle 1, followed by standard dosing of 16 mg/kg for subsequent doses administered weekly from Weeks 2 to 8, every two weeks from Weeks 9 to 24, and every four weeks from Week 25 and thereafter.

View full prescribing information for KYPROLIS.
View full prescribing information for DARZALEX.

This review used  the Assessment Aid, a voluntary submission from the applicants to facilitate the FDA’s assessment. The FDA approved the carfilzomib and daratumumab applications 3 and 4 months ahead of the FDA goal dates, respectively.

Healthcare professionals should report all serious adverse events suspected to be associated with the use of any medicine and device to FDA’s MedWatch Reporting System or by calling 1-800-FDA-1088.

For assistance with single-patient INDs for investigational oncology products, healthcare professionals may contact OCE’s Project Facilitate at 240-402-0004 or email OncProjectFacilitate@fda.hhs.gov.

For information on the COVID-19 pandemic, see the following resources:

Follow the Oncology Center of Excellence on Twitter @FDAOncology.

 

 

Back to Top